Skip to main content

Table 5 Phamacokinetics results for imaging part (A) and therapeutic part (B)

From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

Parameter Cmax Tmax T1/2 AUC C0-336a CL Vdss
Units ng/mL Hours Hours ng*Hours/mL mL/Hours mL
A. Imaging Part (n = 17)
 Mean 483.8 1.3 265.7 154,724 38.6 3311.9
 S.D. 193.3 2.2 316.9 378,371 15.9 998.3
 %CV 39.9 167.9 119.3 244.55 41.3 30.3
B. Therapeutic part (n = 8)
ARM A (370 MBq, n = 3)
 Mean 365.4 0.00 87.4 42,106.7 255.4 4950.0
 S.D. 240.3   66.6 38,489.5 391.9 4811.6
 %CV 65.7   76.2 91.41 153.5 97.2
ARM B (1100 MBq, n = 4b)
 Mean 362.0 1.0 61.8 38,275.0 63.0 1787.7
 S.D. 112.2 1.1 29.0 15,024.7 46.1 1040.5
 %CV 31.0 115.5 46.9 39.25 73.1 58.2
  1. NB: PK data were not analyzed for patients ID 01–0018, 01–019, 01–020 due to premature study and OTS-France closure
  2. aor AUC extrapolated and BLQ concentration set to zero. bdata following the 2nd injection of patient 01–003 are included